Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHB4 | P54760 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ALDH2 | P05091 | 3/20 | 0.34 |
| ▸ | CASP6 | P55212 | 1/20 | 0.33 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.33 |
| ▸ | TEK | Q02763 | 5/20 | 0.33 |
| ▸ | KDR | P35968 | 3/20 | 0.32 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3049024 | 0.86 | LMNA (0.41) | EPHB4POLBTEKKDRL3MBTL1 | |
| SCHEMBL3051555 | 0.86 | QPCT (0.38) | POLBPRKD1 | |
| SCHEMBL3034900 | 0.85 | TEK (0.43) | EPHB4TEKKDRROCK2NOD1 | |
| SCHEMBL3051311 | 0.85 | QPCT (0.37) | POLBPRKD1 | |
| SCHEMBL3047194 | 0.83 | HTT (0.35) | EPHB4POLBPRKD1TEK | |
| SCHEMBL3037465 | 0.83 | POLB (0.33) | EPHB4POLBPRKD1TEKL3MBTL1 | |
| SCHEMBL3041969 | 0.82 | QPCT (0.37) | — | |
| SCHEMBL3044920 | 0.78 | MTOR (0.36) | — | |
| Trifluoroacetic Acid SCHEMBL3038466 | 0.77 | EPHB4 (0.39) | EPHB4CASP6 | |
| SCHEMBL3823826 | 0.76 | MAOB (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | OPRL1, OPRM1, OPRK1 | EPHB4 950/4885POLB 4000/4885ALDH2 3983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.